LBA60 Phase III study of SHR-1701 versus placebo in combination with chemo as first-line (1L) therapy for HER2-negative gastric/gastroesophageal junction adenocarcinoma (G/GEJA)
Authors:
- Z. PengZPZ. Peng
- J. WangJWJ. Wang
- Y. ZhangYZY. Zhang
- H. LiHLH. Li
- Q. ZhaoQZQ. Zhao
- X. ZhuXZX. Zhu
- S. WeiSWS. Wei
- Y. ChengYCY. Cheng
- W. YangWYW. Yang
- J. YaoJYJ. Yao
- M. ZhangMZM. Zhang
- L. XieLXL. Xie
- 17 September 2024
- journal article
- Published by Elsevier in Annals of Oncology
- Vol. 35, S1250